These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

448 related items for PubMed ID: 24829358

  • 1. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
    Awasthi S, Huang J, Shaw C, Friedman HM.
    J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
    [Abstract] [Full Text] [Related]

  • 2. A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection.
    Hook LM, Awasthi S, Dubin J, Flechtner J, Long D, Friedman HM.
    Vaccine; 2019 Jan 21; 37(4):664-669. PubMed ID: 30551986
    [Abstract] [Full Text] [Related]

  • 3. A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model.
    Awasthi S, Hook LM, Shaw CE, Friedman HM.
    Hum Vaccin Immunother; 2017 Dec 02; 13(12):2785-2793. PubMed ID: 28481687
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.
    Awasthi S, Lubinski JM, Shaw CE, Barrett SM, Cai M, Wang F, Betts M, Kingsley S, Distefano DJ, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM.
    J Virol; 2011 Oct 02; 85(20):10472-86. PubMed ID: 21813597
    [Abstract] [Full Text] [Related]

  • 6. An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs.
    Awasthi S, Hook LM, Shaw CE, Pahar B, Stagray JA, Liu D, Veazey RS, Friedman HM.
    PLoS Pathog; 2017 Jan 02; 13(1):e1006141. PubMed ID: 28103319
    [Abstract] [Full Text] [Related]

  • 7. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.
    Awasthi S, Belshe RB, Friedman HM.
    J Infect Dis; 2014 Aug 15; 210(4):571-5. PubMed ID: 24652496
    [Abstract] [Full Text] [Related]

  • 8. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.
    Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, Cai M, Lubinski JM, Barrett SM, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM.
    J Virol; 2012 Apr 15; 86(8):4586-98. PubMed ID: 22318147
    [Abstract] [Full Text] [Related]

  • 9. A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.
    Wang K, Goodman KN, Li DY, Raffeld M, Chavez M, Cohen JI.
    J Virol; 2016 Jan 01; 90(1):562-74. PubMed ID: 26559846
    [Abstract] [Full Text] [Related]

  • 10. Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection.
    Egan K, Hook LM, Naughton A, Friedman HM, Awasthi S.
    Hum Vaccin Immunother; 2020 Sep 01; 16(9):2109-2113. PubMed ID: 32347775
    [Abstract] [Full Text] [Related]

  • 11. Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.
    Awasthi S, Hook LM, Swaminathan G, Cairns TM, Brooks B, Smith JS, Ditto NT, Gindy ME, Bett AJ, Espeseth AS, Cohen GH, Friedman HM.
    Vaccine; 2019 Jun 27; 37(29):3770-3778. PubMed ID: 31153687
    [Abstract] [Full Text] [Related]

  • 12. Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.
    Awasthi S, Shaw C, Friedman H.
    Expert Rev Vaccines; 2014 Dec 27; 13(12):1475-88. PubMed ID: 25138572
    [Abstract] [Full Text] [Related]

  • 13. Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.
    Hook LM, Cairns TM, Awasthi S, Brooks BD, Ditto NT, Eisenberg RJ, Cohen GH, Friedman HM.
    PLoS Pathog; 2018 May 27; 14(5):e1007095. PubMed ID: 29791513
    [Abstract] [Full Text] [Related]

  • 14. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
    Çuburu N, Wang K, Goodman KN, Pang YY, Thompson CD, Lowy DR, Cohen JI, Schiller JT.
    J Virol; 2015 Jan 27; 89(1):83-96. PubMed ID: 25320297
    [Abstract] [Full Text] [Related]

  • 15. A Trivalent HSV-2 gC2, gD2, gE2 Nucleoside-Modified mRNA-LNP Vaccine Provides Outstanding Protection in Mice against Genital and Non-Genital HSV-1 Infection, Comparable to the Same Antigens Derived from HSV-1.
    Egan KP, Awasthi S, Tebaldi G, Hook LM, Naughton AM, Fowler BT, Beattie M, Alameh MG, Weissman D, Cohen GH, Friedman HM.
    Viruses; 2023 Jun 30; 15(7):. PubMed ID: 37515169
    [Abstract] [Full Text] [Related]

  • 16. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT, Marshall JD, Dorwart MR, Heeke DS, Rao E, Tummala P, Yu L, Cohen GH, Eisenberg RJ, Sloan DD.
    J Virol; 2017 May 01; 91(9):. PubMed ID: 28228587
    [Abstract] [Full Text] [Related]

  • 17. Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes.
    Awasthi S, Hook LM, Pardi N, Wang F, Myles A, Cancro MP, Cohen GH, Weissman D, Friedman HM.
    Sci Immunol; 2019 Sep 20; 4(39):. PubMed ID: 31541030
    [Abstract] [Full Text] [Related]

  • 18. Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.
    Awasthi S, Balliet JW, Flynn JA, Lubinski JM, Shaw CE, DiStefano DJ, Cai M, Brown M, Smith JF, Kowalski R, Swoyer R, Galli J, Copeland V, Rios S, Davidson RC, Salnikova M, Kingsley S, Bryan J, Casimiro DR, Friedman HM.
    J Virol; 2014 Feb 20; 88(4):2000-10. PubMed ID: 24284325
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4+ and CD8+ TRM Cells Associated with Protection against Recurrent Genital Herpes.
    Srivastava R, Roy S, Coulon PG, Vahed H, Prakash S, Dhanushkodi N, Kim GJ, Fouladi MA, Campo J, Teng AA, Liang X, Schaefer H, BenMohamed L.
    J Virol; 2019 May 01; 93(9):. PubMed ID: 30787156
    [Abstract] [Full Text] [Related]

  • 20. A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.
    Ramsey NLM, Visciano M, Hunte R, Loh LN, Burn Aschner C, Jacobs WR, Herold BC.
    J Virol; 2020 Jun 16; 94(13):. PubMed ID: 32295919
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.